Greenwich Lifesciences Stock Analysis

GLSI Stock  USD 13.19  0.06  0.45%   
Greenwich Lifesciences is undervalued with Real Value of 18.84 and Target Price of 38.0. The main objective of Greenwich Lifesciences stock analysis is to determine its intrinsic value, which is an estimate of what Greenwich Lifesciences is worth, separate from its market price. There are two main types of Greenwich Lifesciences' stock analysis: fundamental analysis and technical analysis.
The Greenwich Lifesciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Greenwich Lifesciences' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.

Greenwich Stock Analysis Notes

About 53.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.81. Greenwich Lifesciences had not issued any dividends in recent years. Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Greenwich Lifesciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. To learn more about Greenwich Lifesciences call Snehal Patel at 832 819 3232 or check out https://greenwichlifesciences.com.

Greenwich Lifesciences Investment Alerts

Greenwich Lifesciences had very high historical volatility over the last 90 days
Greenwich Lifesciences has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (8.89 M) with profit before overhead, payroll, taxes, and interest of 0.
Greenwich Lifesciences currently holds about 15.64 M in cash with (6.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22.
Greenwich Lifesciences has a frail financial position based on the latest SEC disclosures
Roughly 53.0% of the company shares are held by company insiders
Latest headline from news.google.com: Major Breakthrough Cancer Prevention Trial Goes Europe-Wide as Top Medical Centers Join Forces - StockTitan

Greenwich Lifesciences Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Greenwich Lifesciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
29th of March 2024
Upcoming Quarterly Report
View
27th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Greenwich Largest EPS Surprises

Earnings surprises can significantly impact Greenwich Lifesciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-15
2021-09-30-0.06-0.07-0.0116 
2023-10-19
2023-09-30-0.22-0.18620.033815 
2023-03-01
2022-12-31-0.18-0.22-0.0422 
View All Earnings Estimates

Greenwich Lifesciences Environmental, Social, and Governance (ESG) Scores

Greenwich Lifesciences' ESG score is a quantitative measure that evaluates Greenwich Lifesciences' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Greenwich Lifesciences' operations that may have significant financial implications and affect Greenwich Lifesciences' stock price as well as guide investors towards more socially responsible investments.

Greenwich Stock Institutional Investors

Shares
Bank Of New York Mellon Corp2024-09-30
11.2 K
Millennium Management Llc2024-09-30
10.6 K
Barclays Plc2024-09-30
8.6 K
Rhumbline Advisers2024-09-30
6.3 K
New York State Common Retirement Fund2024-09-30
K
Bank Of America Corp2024-09-30
5.9 K
Citigroup Inc2024-09-30
4.3 K
Mirae Asset Global Etfs Holdings Ltd.2024-09-30
3.3 K
Corebridge Financial Inc2024-09-30
3.2 K
Blackrock Inc2024-09-30
350.1 K
Vanguard Group Inc2024-09-30
273.5 K
Note, although Greenwich Lifesciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Greenwich Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 173.38 M.

Greenwich Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(1.14)(1.20)
Return On Capital Employed(1.60)(1.52)
Return On Assets(1.14)(1.20)
Return On Equity(1.53)(1.45)

Management Efficiency

Greenwich Lifesciences has return on total asset (ROA) of (0.7245) % which means that it has lost $0.7245 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2367) %, meaning that it created substantial loss on money invested by shareholders. Greenwich Lifesciences' management efficiency ratios could be used to measure how well Greenwich Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.2. The Greenwich Lifesciences' current Return On Capital Employed is estimated to increase to -1.52. As of now, Greenwich Lifesciences' Other Assets are decreasing as compared to previous years.
Last ReportedProjected for Next Year
Book Value Per Share 0.52  0.47 
Tangible Book Value Per Share 0.52  0.47 
Enterprise Value Over EBITDA(12.37)(12.99)
Price Book Value Ratio 18.16  19.06 
Enterprise Value Multiple(12.37)(12.99)
Price Fair Value 18.16  19.06 
Enterprise Value147.4 M240.3 M
Leadership at Greenwich Lifesciences emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta
3.318
Return On Assets
(0.72)
Return On Equity
(1.24)

Technical Drivers

As of the 31st of January, Greenwich Lifesciences retains the Downside Deviation of 3.65, market risk adjusted performance of 0.0144, and Risk Adjusted Performance of 0.0109. Greenwich Lifesciences technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Greenwich Lifesciences Price Movement Analysis

Execute Study
The output start index for this execution was fourty-four with a total number of output elements of seventeen. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Greenwich Lifesciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Greenwich Lifesciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Greenwich Lifesciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Greenwich Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Greenwich Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Greenwich Lifesciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Snehal Patel over two weeks ago
Acquisition by Snehal Patel of 2500 shares of Greenwich Lifesciences at 12.51 subject to Rule 16b-3
 
Snehal Patel over a month ago
Acquisition by Snehal Patel of 3200 shares of Greenwich Lifesciences at 11.12 subject to Rule 16b-3
 
Mcwilliams David over a month ago
Acquisition by Mcwilliams David of 61984 shares of Greenwich Lifesciences at 12.16 subject to Rule 16b-3
 
Jaye Thompson over two months ago
Acquisition by Jaye Thompson of 1000 shares of Greenwich Lifesciences at 12.91 subject to Rule 16b-3
 
Snehal Patel over two months ago
Acquisition by Snehal Patel of 2000 shares of Greenwich Lifesciences at 9.72 subject to Rule 16b-3
 
Snehal Patel over three months ago
Acquisition by Snehal Patel of 12000 shares of Greenwich Lifesciences at 7.91 subject to Rule 16b-3
 
Snehal Patel over three months ago
Acquisition by Snehal Patel of 1500 shares of Greenwich Lifesciences at 14.63 subject to Rule 16b-3
 
Snehal Patel over three months ago
Acquisition by Snehal Patel of 2000 shares of Greenwich Lifesciences at 13.81 subject to Rule 16b-3
 
Snehal Patel over three months ago
Acquisition by Snehal Patel of 5500 shares of Greenwich Lifesciences at 13.18 subject to Rule 16b-3
 
Jaye Thompson over six months ago
Acquisition by Jaye Thompson of 1000 shares of Greenwich Lifesciences at 15.15 subject to Rule 16b-3
 
Snehal Patel over six months ago
Acquisition by Snehal Patel of 1500 shares of Greenwich Lifesciences at 15.89 subject to Rule 16b-3
 
Jaye Thompson over six months ago
Acquisition by Jaye Thompson of 1000 shares of Greenwich Lifesciences at 16.0 subject to Rule 16b-3

Greenwich Lifesciences Outstanding Bonds

Greenwich Lifesciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Greenwich Lifesciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Greenwich bonds can be classified according to their maturity, which is the date when Greenwich Lifesciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Greenwich Lifesciences Predictive Daily Indicators

Greenwich Lifesciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Greenwich Lifesciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Greenwich Lifesciences Corporate Filings

F4
13th of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
8th of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
7th of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
6th of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
3rd of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
2nd of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
27th of December 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
20th of December 2024
Other Reports
ViewVerify

Greenwich Lifesciences Forecast Models

Greenwich Lifesciences' time-series forecasting models are one of many Greenwich Lifesciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Greenwich Lifesciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Greenwich Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Greenwich Lifesciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Greenwich shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Greenwich Lifesciences. By using and applying Greenwich Stock analysis, traders can create a robust methodology for identifying Greenwich entry and exit points for their positions.
Last ReportedProjected for Next Year

Current Greenwich Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Greenwich analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Greenwich analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
38.0Buy1Odds
Greenwich Lifesciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Greenwich analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Greenwich stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Greenwich Lifesciences, talking to its executives and customers, or listening to Greenwich conference calls.
Greenwich Analyst Advice Details

Greenwich Stock Analysis Indicators

Greenwich Lifesciences stock analysis indicators help investors evaluate how Greenwich Lifesciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Greenwich Lifesciences shares will generate the highest return on investment. By understating and applying Greenwich Lifesciences stock analysis, traders can identify Greenwich Lifesciences position entry and exit signals to maximize returns.
Begin Period Cash Flow13.5 M
Total Stockholder Equity6.7 M
Cash And Short Term InvestmentsM
Net Invested Capital6.7 M
Shares Float5.9 M
CashM
200 Day M A14.005
50 Day M A12.9538
Net Interest Income450.9 K
Total Current Liabilities294.4 K
Stock Based Compensation2.4 M
Common Stock Shares Outstanding12.8 M
Free Cash Flow-6.5 M
Operating Income-9.3 M
Accounts Payable35.5 K
Net Debt-7 M
Depreciation3612.00
TypeCommon Stock
Other Operating Expenses9.3 M
Non Current Assets Total5391.00
E P S Estimate Current Quarter-0.21
Total Current AssetsM
Liabilities And Stockholders EquityM
Income Before Tax-8.9 M
Capital Stock12.8 K

Complementary Tools for Greenwich Stock analysis

When running Greenwich Lifesciences' price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Bonds Directory
Find actively traded corporate debentures issued by US companies
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance